Explain the specific (toxicities) that led to these discontinuations. Compare these results to more recent ibrutinib studies .
This article, available through PubMed Central (PMC) , provides a comprehensive look at how the drug performs in real-world clinical settings compared to controlled trials. Study Overview: The 616-Patient Cohort (616 KB)
: Patients in clinical trials were generally younger, with a mean age of 58 compared to 61 in this real-world group. Explain the specific (toxicities) that led to these
: Despite the high rate of stopping, the overall survival and progression-free survival (estimated at 35 months) remained excellent. Real-World vs. Clinical Trials available through PubMed Central (PMC)
: A major finding was that 41% of patients stopped taking ibrutinib within a median of 17 months.